Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclophosphamide is a DNA-alkylating chemotherapeutic agent that is metabolically activated to phosphoramide mustard, which forms covalent bonds (alkyl adducts) at the N-7 position of guanine bases in DNA[1][2][6]. The most cytotoxic lesions are interstrand DNA crosslinks, in which two guanine bases on opposite DNA strands are covalently linked, preventing the strands from separating for replication or transcription[1][5]. These crosslinks, if unrepaired, block cell division and lead to programmed cell death (apoptosis)[2][4]. Cyclophosphamide-induced DNA crosslinks are central to the drug's anti-cancer and immunosuppressive effects, but also underlie many of its toxicities in non-cancerous cells, contributing to risks such as myelosuppression and secondary malignancies[4][5]. This entry describes a drug-induced DNA modification/lesion (DNA interstrand cross-link) rather than a canonical molecular target such as a protein, enzyme, or receptor. While this lesion is central to the mechanism of action of cyclophosphamide, it is an *effect* of the drug's interaction with DNA, not the 'target' itself in a conventional sense. The direct molecular target for cyclophosphamide is the guanine base within genomic DNA. Therefore, according to target classification conventions, this entry is marked as 'is_incorrect: true' for a target database, as it represents a biomolecular event or drug effect rather than a discrete, regulatable molecular entity.
Cyclophosphamide is metabolized in the liver to form phosphoramide mustard, which alkylates the N-7 position of guanine, resulting in intra- and interstrand DNA crosslinks. These covalent interstrand crosslinks inhibit DNA replication and transcription, leading to cell death if the lesion cannot be repaired. If cross-links cannot be repaired, p53 activation leads to cell cycle arrest and subsequent programmed cell death (apoptosis).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA interstrand cross-link (induced by cyclophosphamide alkylation of guanine).